Clopidogrel coated tablets 0.075 g. №30


Manufacturer: Ukraine



Prevention of atherothrombosis in adults: who have suffered a myocardial infarction (starting treatment-a few days, but not later than 35 days after occurrence), ischemic stroke (starting treatment-7 days, but not later than 6 months after occurrence) or who have been diagnosed with peripheral artery disease (arterial damage and atherothrombosis of the lower extremities); with acute coronary syndrome: without St-segment elevation (unstable angina or myocardial infarction without q-wave), including in patients who received a stent during percutaneous coronary angioplasty, in combination with acetylsalicylic acid (aSA); with acute myocardial infarction with St segment elevation in combination with acetylsalicylic acid (in patients receiving standard medical treatment and who are indicated for thrombolytic therapy). Prevention of atherothrombotic and thromboembolic events in atrial fibrillation. Clopidogrel in combination with ASC is indicated in adult patients with atrial fibrillation who have at least one risk factor for vascular events, who have contraindications to treatment with Vitamins K antagonists (aVC) and who have a low risk of bleeding, for the prevention of atherothrombotic and thromboembolic events, including stroke. See also the section “Pharmacological properties”.